0000886163-19-000177.txt : 20190924
0000886163-19-000177.hdr.sgml : 20190924
20190924191101
ACCESSION NUMBER: 0000886163-19-000177
CONFORMED SUBMISSION TYPE: 4/A
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190919
FILED AS OF DATE: 20190924
DATE AS OF CHANGE: 20190924
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HIGGINS JOHN L
CENTRAL INDEX KEY: 0001208906
FILING VALUES:
FORM TYPE: 4/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33093
FILM NUMBER: 191111767
MAIL ADDRESS:
STREET 1: 11119 NORTH TORREY PINES ROAD, SUITE 200
CITY: LA JOLLA
STATE: CA
ZIP: 92037
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LIGAND PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000886163
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 770160744
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-550-7500
MAIL ADDRESS:
STREET 1: 3911 SORRENTO VALLEY BLVD
STREET 2: SUITE 110
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
4/A
1
edgardoc.xml
PRIMARY DOCUMENT
X0306
4/A
2019-09-19
2019-09-23
0
0000886163
LIGAND PHARMACEUTICALS INC
LGND
0001208906
HIGGINS JOHN L
3911 SORRENTO VALLEY BOULEVARD, STE 110
SAN DIEGO
CA
92121
1
1
0
0
Chief Executive Officer
0.75% Convertible Senior Notes due 2023
248.48
2019-09-19
4
P
0
1175000
988468.75
A
2023-05-15
Common Stock
4729.0
1175000
D
This amendment is being filed to correct the amount of securities purchased. The original Form 4 reported that the principal amount of 0.75% Convertible Senior Notes due 2023 was $1,000,000 with a purchase price of $841,250. The reporting person actually purchased $1,175,000 principal amount for a purchase price of $988,468.75 on the transaction date.
The notes are convertible at any time prior to the close of business on November 14, 2022 (1) during any fiscal quarter (and only during such fiscal quarter) commencing after September 30, 2018, if, for at least 20 trading days (whether or not consecutive) during the 30 consecutive trading day period ending on the last trading day of the immediately preceding fiscal quarter, the last reported sale price of the Issuer?s common stock on such trading day is greater than 130% of the conversion price on such trading day; (2) during the five business day period immediately following any 10 consecutive trading day period, in which the trading price per $1,000 principal amount of notes was less than 98% of the product of the last reported sale price of our common stock on such trading day and the conversion rate on each such trading day; or (3) upon the occurrence of certain specified corporate events as specified in the indenture governing the notes.
By: Charles S. Berkman For: John L. Higgins
2019-09-24